

# ***In vivo* role of INPP4B in tumor and metastasis suppression through regulation of PI3K/AKT signaling at endosomes**

**Chen Li Chew<sup>1</sup>, Andrea Lunardi<sup>1\*</sup>, Federico Gulluni<sup>2\*</sup>, Daniel T. Ruan<sup>1</sup>, Ming Chen<sup>1</sup>, Leonardo Salmena<sup>1,6</sup>, Michiya Nishino<sup>3</sup>, Antonella Papa<sup>1</sup>, Christopher Ng<sup>1</sup>, Jacqueline Fung<sup>1</sup>, John G. Clohessy<sup>1</sup>, Junko Sasaki<sup>4</sup>, Takehiko Sasaki<sup>4</sup>, Roderick T. Bronson<sup>5</sup>, Emilio Hirsch<sup>2</sup> and Pier Paolo Pandolfi<sup>1</sup>**

<sup>1</sup>*Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.* <sup>2</sup>*Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy.* <sup>3</sup>*Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.* <sup>4</sup>*Department of Medical Biology, Akita University Graduate School of Medicine and Research Center for Biosignal, Akita University, Akita 010-8543, Japan.* <sup>5</sup>*Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02215 USA.* <sup>6</sup>*Present address: Department of Pharmacology and Toxicology, University of Toronto and Princess Margaret Cancer Center, Toronto ON M5T 2M9, Canada.*

\*These authors contributed equally to this article.

**Correspondence should be addressed to:** Pier Paolo Pandolfi

Beth Israel Deaconess Medical Center, CLS Building, Room 401  
330 Brookline Avenue, Boston, MA 02215.  
Phone: 617-735-2121; Email: [ppandolfi@bidmc.harvard.edu](mailto:ppandolfi@bidmc.harvard.edu)

**Running title:** INPP4B inhibits thyroid tumorigenesis and metastasis

**Keywords:** Cancer, metastasis, genetics, INPP4B, endosome, PI3K/AKT, thyroid

**Conflict of Interest:** None of the authors have anything to declare

## ABSTRACT

The phosphatases PTEN and INPP4B have been proposed to act as tumor suppressors by antagonizing PI3K/AKT signaling, and are frequently dysregulated in human cancer. While PTEN has been extensively studied, little is known about the underlying mechanisms by which INPP4B exerts its tumor suppressive function and its role in tumorigenesis *in vivo*. Here, we show that a partial or complete loss of *Inpp4b* morphs benign thyroid adenoma lesions in *Pten* heterozygous mice into lethal and metastatic follicular-like thyroid cancer (FTC). Importantly, analyses of human thyroid cancer cell lines and specimens reveal INPP4B downregulation in FTC. Mechanistically, we find that INPP4B, but not PTEN, is enriched in the early endosomes of thyroid cancer cells, where it selectively inhibits AKT2 activation and in turn tumor proliferation and anchorage-independent growth. We therefore identify INPP4B as a novel tumor suppressor in FTC oncogenesis and metastasis through localized regulation of PI3K/AKT pathway at the endosomes.

## SIGNIFICANCE

Although both PTEN and INPP4B can inhibit PI3K/AKT signaling through their lipid phosphatase activities, here we demonstrate lack of an epistatic relationship between the two tumor suppressors. Instead, the qualitative regulation of PI3K/AKT2 signaling by INPP4B provides a mechanism for their cooperation in suppressing thyroid tumorigenesis and metastasis.

## INTRODUCTION

The phosphoinositide 3-kinase (PI3K)/AKT signaling pathway modulates important biological processes such as cell cycle, survival, metabolism and motility, which are often disrupted in cancer (1). Hyperactivation of the PI3K/AKT pathway leads to an accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P<sub>3</sub>), which in turn increases the recruitment and activation of protein kinase AKT at the cytoplasmic membrane (1), a key mediator of the oncogenic effects of enhanced PI3K signaling.

The AKT protein kinase family is made up of three highly homologous isoforms, namely AKT1, AKT2 and AKT3 (2). Despite similarities in sequence and regulation, studies reveal isoform-specific functions in cancer progression. In the context of breast cancer, overexpression of AKT2 promotes metastasis (3), while AKT1 suppresses metastasis (4, 5). The distinct functions of the AKT isoforms could be explained, at least in part, through the association of the AKT isoforms with distinct organelles or subcellular compartments (2).

The tumor suppressor gene *PTEN* (the phosphatase and tensin homolog), encoding a lipid-phosphatase, dephosphorylates PI(3,4,5)P<sub>3</sub> to PI(4,5)P<sub>2</sub> to antagonize PI3K/AKT signaling. To study the effects of *Pten* loss *in vivo*, we previously generated mouse models with constitutive and conditional *Pten* loss (6). We found that homozygous loss of *Pten* results in embryonic lethality, while *Pten* heterozygous (*Pten*<sup>+/-</sup>) mice develop tumors of the breast, endometrium, prostate, adrenal, pituitary and lymphoma (7). More recently, INPP4B (inositol polyphosphate-phosphatase type II), another dual specificity and lipid phosphatase, has emerged as a putative tumor suppressor in the suppression of the PI3K/AKT signaling pathway. *INPP4B* was initially identified as an anchorage independent growth suppressor in a shRNA-mediated genetic screen

performed in HMEC cells (8), and was found to inhibit PI3K signaling and to display tumor suppressive activity in breast tumor cell lines (9). In agreement with these findings, INPP4B expression was found to be reduced in basal-like breast cancers (9, 10), melanoma (11), nasopharyngeal carcinoma (12), and prostate cancer (13). Furthermore, expression-profiling analyses revealed that INPP4B mRNA expression is reduced in up to 47% of metastatic prostate cancer cases (14), implicating the potential role of INPP4B in metastatic progression.

INPP4B converts PI(3,4)P<sub>2</sub> to PI(3)P and because direct interaction of PI(3,4)P<sub>2</sub> with the pleckstrin homology (PH) domain of AKT is required for membrane recruitment and full activation of AKT (15), INPP4B, like PTEN, is anticipated to act as a tumor suppressor by antagonizing PI3K/AKT signaling (9). However, unlike PTEN, the underlying molecular mechanisms by which INPP4B exerts its tumor suppressive function are poorly understood. Additionally it is not known whether INPP4B acts as a tumor suppressor *in vivo*.

We therefore sought to investigate the tumor suppressive functions of INPP4B *in vivo* in Knock-out (KO) mouse models. Surprisingly, we found that INPP4B exerts a specific role in the suppression of thyroid tumorigenesis and metastasis *in vivo* through the inhibition of PI3K-C2 $\alpha$  mediated AKT2 activation at endosomes.

## RESULTS

### **Inpp4b knockout (*Inpp4b*<sup>-/-</sup>) mice do not develop the tumorigenic phenotype of *Pten* haploinsufficient mice.**

To determine the *in vivo* tumor suppressive function of INPP4B, we took advantage of *Inpp4b* knockout mice (*Inpp4b*<sup>-/-</sup>) generated by using a homologous recombination targeting strategy in which the conditional targeting vector was constructed to delete exon 21 of the mouse *Inpp4b* gene, which encodes the phosphatase catalytic domain (Fig. 1A-B). Unlike *Pten*<sup>-/-</sup> mice, *Inpp4b*<sup>-/-</sup> mice were viable and born in accordance to Mendelian frequencies (Fig. 1C). Furthermore, *Inpp4b*<sup>+/-</sup> and *Inpp4b*<sup>-/-</sup> mice did not develop any of the tumors or the lymphoproliferative disease characteristic of *Pten*<sup>+/-</sup> mice in a 16-24 months follow-up (16). Aggressive and fatal, albeit sporadic, histiosarcomas were observed after a very long latency in *Inpp4b*<sup>-/-</sup> mice (data not shown). These results demonstrate unequivocally that the role of PTEN and INPP4B in tumorigenesis could be very distinct.

### **Loss of *Inpp4b* in a *Pten* heterozygous background leads to metastatic follicular-like thyroid carcinoma.**

We next sought to determine if loss of *Inpp4b* cooperated with *Pten* loss to promote tumor progression. We hypothesized that loss of *Inpp4b* would accelerate overall tumor progression in *Pten*<sup>+/-</sup> mice, keeping with their reported epistatic relationship in the suppression of PI3K/AKT signaling. To this end, we crossed *Pten*<sup>+/-</sup> mice with *Inpp4b*<sup>-/-</sup> mice. The resulting *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> mice were then crossed with *Inpp4b*<sup>+/-</sup> littermates to generate wild type, *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice (Suppl. Fig. 1A). These mice were, once again, viable

and born following the expected Mendelian frequencies (Fig. 1C). The lack of embryonic lethality in any of the two compound  $Pten^{+/-}Inpp4b^{+/-}$  and  $Pten^{+/-}Inpp4b^{-/-}$  genetic make-ups further underscore the fact that PTEN and INPP4B might exert distinct roles in signaling since the progressive PI3K/AKT elevation should result in embryonic lethality as previously reported (6).

However,  $Pten^{+/-}Inpp4b^{-/-}$  mice did not survive beyond 5-6 months of age, while the majority  $Pten^{+/-}Inpp4b^{+/-}$  mice died between 8 and 14 months of age (Fig. 2A). Gross anatomical analyses showed that the  $Pten^{+/-}Inpp4b^{-/-}$  mice developed large multinodular goiters (Fig. 2B). These mice died, or were euthanized, after developing compressive airway and esophageal obstruction as a consequence of the mass effect from thyroid enlargement. Histopathological analyses revealed that most of the thyroid tumors developed in the  $Pten^{+/-}Inpp4b^{-/-}$  mice had variable degrees of encapsulation (Fig. 2C and 2D, top left), microfollicular architecture (Fig. 2C, left middle panel) and many showed impressive vascular invasion closely resembling follicular thyroid carcinoma (FTC) in human. High-grade features were commonly seen, including significant mitotic activity and necrosis, while some portion of the tumors showed nuclear features of follicular variant papillary thyroid carcinoma (FV-PTC), such as nuclear contour irregularity, nuclear grooves, intranuclear pseudoinclusions and chromatin pallor (Fig. 2C, right panels). Collectively, the majority of tumors in  $Pten^{+/-}Inpp4b^{-/-}$  mice displayed histological and pathological features of FTC and FV-PTC in human (Fig. 2C and 2D, top). Importantly, 50% of  $Pten^{+/-}Inpp4b^{-/-}$  mice developed diffuse pulmonary metastases (Fig. 2D, top right). These metastases had the histologic appearance of thyroid tissue with follicular architecture, colloid, and also stained positive for thyroglobulin, a thyroid specific marker (Fig. 2D, middle panel). Necropsy did not reveal metastases in other regional and distant sites. Akt

activation was observed by immunohistochemistry in both the thyroid tumors and the metastases (Fig. 2D, bottom panel). Serum TSH levels of *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice did not differ significantly from that in *Pten*<sup>+/-</sup> mice (Suppl. Fig. 1B). Additionally, we examined the thyroids from a cohort of *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> mice. Histopathological analyses revealed that *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> mice developed benign goiter and FVPTC/FTC, and presented with pulmonary metastases of thyroid carcinoma at a similar penetrance to *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice (Suppl. Fig. 1C). Furthermore, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice did not display accelerated tumorigenesis in other tissues as compared to *Pten*<sup>+/-</sup> mice by 5-8 months follow-up (data not shown). However, we did note a non-significant increased incidence of breast adenocarcinoma in *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> mice (p=0.16, 37.5% in *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> vs 15.5% in *Pten*<sup>+/-</sup> mice). Therefore, *Inpp4b* loss cooperates with *Pten* haploinsufficiency to promote thyroid cancer progression and metastasis.

### **Human follicular thyroid cancer cell lines and tissues display low INPP4B expression.**

To assess the relevance of our mouse model findings to human FTC, we evaluated the status of INPP4B in human thyroid cancer cells. To this end we utilized seven thyroid cell lines, namely Nthy-Ori 3, Htori (SV40-immortalized primary thyroid follicular epithelial cells), FTC133, FTC236, FTC238 (follicular thyroid carcinoma), TPC1 (thyroid papillary carcinoma), and 8505C (anaplastic carcinoma). We first determined the relative expression levels of *INPP4B* in these thyroid cell lines. We observed very low expression of INPP4B at both protein (Fig. 3A, Suppl. Fig. 2) and mRNA transcript levels (Fig. 3B) in the FTC cell lines FTC133, FTC236 and FTC238 compared to SV40-immortalized human thyroid follicular cells Nthy-Ori-3 and Htori or

the TPC1 thyroid cancer cell line. We also noted that PTEN protein expression was not detectable in the FTC cell lines (Fig. 3A). A search using the Broad CCLE database revealed that the FTC cell lines harbor the PTEN R130\* nonsense mutation. This concomitant loss of PTEN and INPP4B in our human FTC cell lines is faithfully modelled by our *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice. Finally, we observed an increase in the activation of AKT in these cell lines, as indicated by higher levels of AKT phosphorylation at both Threonine 308 and Serine 473 residues (Fig. 3C).

Importantly, *INPP4B* transcript expression was significantly downregulated in human FTC samples when compared to normal tissue samples (Fig. 3D). Because of the infrequency of INPP4B deletions or mutations in human cancers, we further hypothesized that its loss in FTC cell lines might be due to aberrant gene methylation. Indeed, treatment of these cell lines with 5-Aza-2'-deoxycytidine (5-Aza), which inhibits DNA methylation, increased INPP4B expression approximately 4-fold (Fig. 3E). Upregulation of INPP4B by 5-Aza decreased activation of both AKT1 and AKT2 (Serine 473 and Serine 474 respectively), (Fig. 3F) with a much greater effect on p-AKT2 than on p-AKT1 (Fig. 3F). However, bisulfite sequencing indicated that this upregulation is potentially indirect (Suppl. Fig. S3), mediated via the upregulation of yet to be defined transcription factors. Overall, the downregulation of INPP4B in human FTC strongly supports its tumor suppressive role in this aggressive tumor type of the thyroid.

### **Loss of *Inpp4b* increases Akt activation.**

We previously demonstrated that INPP4B knock down enhanced AKT activation (9). To gain insight into the mechanisms by which *Inpp4b* might promote thyroid tumor development, we analyzed thyroid tumor lysates from *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice for



Akt activation via Western blotting. In agreement with previous findings, tumors from *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice showed higher levels of Akt phosphorylation (monitored through p-Akt1 Serine 473 and p-Akt2 Serine 474) when compared to thyroid tumors obtained from *Pten*<sup>+/-</sup> or *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> mice (Fig. 4A). We also isolated primary mouse embryonic fibroblasts (MEFs) of all genetic combinations – wildtype, *Inpp4b*<sup>flox/flox</sup>; *Inpp4b*<sup>flox/+</sup>; *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup>, and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup>. We found that MEFs with *Inpp4b* deletion displayed increased Akt activation, monitored through the phosphorylation of both Serine 473 and Threonine 308 at different time points after serum stimulation (Suppl. Fig. S4). In addition, although *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup>, and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> MEFs did not display much higher initial Akt activation upon serum starvation-restimulation (Fig. 4B, t=5 mins and 15 mins), there was a prolonged Akt-1 and Akt2 activation in *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup>, and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> MEFs when compared to *Pten*<sup>+/-</sup> MEFs (Fig. 4B, t=30 mins). Furthermore, we found that human thyroid cancer cell lines with lower INPP4B displayed higher levels of AKT phosphorylation (Fig. 3C and 4C). Notably, both AKT1 and AKT2 were activated to a similar extent in total cell lysates (Fig. 4A, 4B and 4C). Therefore, loss of both lipid phosphatases, INPP4B and PTEN, resulted in an additive activation of AKT in thyroid tissue, MEFs and cancer cell lines.

### **INPP4B suppresses PI3K-C2 $\alpha$ mediated AKT2 activation at early endosomes in thyroid cancer cells.**

The observation that complete inactivation of *Pten* in mouse thyroid results mainly in follicular adenoma within 12 months of age (17) and that *Inpp4b* loss does not accelerate the entire tumor spectrum of *Pten*<sup>+/-</sup> mice raised the possibility that loss of *Inpp4b* specifically

cooperates with *Pten* loss for tumor progression and metastasis in thyroid, not through a generic elevation of PI3K/AKT signaling, but potentially by deregulating the PI3K pathway in a more selective manner. Previous studies have shown that Akt2 deficiency had little-to-no effect on the tumor spectrum in *Pten*<sup>+/-</sup> mice, and only specifically significantly decreased the incidence of thyroid tumors in *Pten*<sup>+/-</sup> mice (18), suggesting that AKT2 might play an oncogenic role in thyroid cancer. Recent studies have shown that AKT2 phosphorylates its substrates on both endosomes and the plasma membrane (19). Strikingly, subcellular fractionation experiments showed that INPP4B, but not PTEN, was expressed in the Rab5-positive early endosomal (EE) fraction together with AKT2 in thyroid cancer cells (Fig. 4D and 4E). Although AKT1 was also localized in the EE fraction (Fig. 4D), surprisingly, knockdown of INPP4B selectively activated AKT2, but not AKT1 in the EE (Fig. 4F). Consistent with this result, thyroid cancer cell lines with lower INPP4B expression display higher endosomal AKT2 activation (Suppl. Fig. S5A). Furthermore, increasing INPP4B expression with 5-Aza in FTC236 cells resulted in a greater decrease in p-AKT2 in the EE fraction compared to p-AKT1 (Fig. 4G). Collectively, these results lend support to the selective activation of AKT2 at the early endosomes by INPP4B.

In line with class II PI3K kinase  $\alpha$  (PI3K-C2 $\alpha$ ) producing PI(3,4)P<sub>2</sub> and being selectively activated in endocytosis as well as endocytic recycling (20, 21), we also found PI3K-C2 $\alpha$  expressed in the thyroid cancer cells and enriched in EE fraction, along with INPP4B and AKT2 (Fig. 4E). The association of INPP4B, AKT2 and PI3K-C2 $\alpha$  with EE was also confirmed by immunofluorescence, in which INPP4B, AKT2 and PI3K-C2 $\alpha$  were co-localized with RAB5-positive punctate structures in the cells (Fig. 4H). Notably, INPP4B loss was associated with increased abundance of PI(3,4)P<sub>2</sub> (Fig. 4I and 4J), but not PI(3,4,5)P<sub>3</sub> (Suppl. Fig. S5B). Consequently, there was an accumulation of the PI(3,4)P<sub>2</sub>-binding protein SNX9 in vesicles near

the plasma membrane (Fig. 4J). Taken together, these results suggest that INPP4B negatively regulates PI3K-C2 $\alpha$  signaling at the EE. Furthermore, loss of PI3K-C2 $\alpha$  decreased AKT2 activation to a greater extent than that of AKT1 in total cell lysates (Suppl. Fig. S6A and S6B) and significantly inhibited cell proliferation in FTC 236 cells (Suppl. Fig. S6C), underscoring the functional relevance of enhanced PI3K-C2 $\alpha$  signaling in cells with lower INPP4B. Taken together, our results strongly suggests that INPP4B inhibits PI3K-C2 $\alpha$  mediated AKT2 activation in the early endosomes of thyroid cancer cells, even though they obviously do not rule out the possible involvement of other PI3K isoforms in AKT activation at the EE.

### **Knockdown of INPP4B in thyroid cell lines provide an advantage for anchorage independent growth.**

To assess INPP4B dependent cellular processes *in vitro*, we next conducted cell proliferation and soft agar colony formation assays in two of the non-FTC thyroid cell lines, namely TPC1 and 8505C, in which we stably knocked down INPP4B (Fig. 5A and 5B). We found that the knockdown of INPP4B did not confer a growth advantage for thyroid cell lines in full or 1% serum growth conditions, but did in 5% serum growth conditions (Fig. 5C and Suppl. Fig. S7A), suggesting that under specific conditions of nutrients or growth factor amounts, INPP4B loss determines a growth advantage in thyroid cell lines, mirroring the *in vivo* phenotype. In addition, INPP4B knock down did not result in any change in TPC1 cell morphology, nor did it alter the morphology of *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> MEFs compared to *Pten*<sup>+/-</sup> MEFs (Suppl. Fig. S7B and S7C). Furthermore, INPP4B loss did not alter the distribution or arrangement of tubulin in the cytoskeleton of these cells (Suppl. Fig. S7B and S7C). Instead, INPP4B loss provided a marked

advantage for anchorage independent growth, a functional indicator of tumorigenicity and invasiveness (Fig. 5D and 5E).

## DISCUSSION

This study allowed us to reach three important conclusions:

First, INPP4B is a novel tumor suppressor in FTC. Through our mouse model, we demonstrated that either a partial or complete loss of *Inpp4b* in a *Pten* heterozygous background accelerates thyroid carcinoma progression, resulting in metastatic disease that recapitulates the hematogenous pulmonary metastases characteristic of advanced FTC in humans. The evidence that INPP4B is a relevant tumor suppressor in FTC is further supported by the observation that INPP4B expression is markedly reduced in human FTC, as compared to a normal thyroid and other subtypes of thyroid cancer.

Our findings lend further support to the notion that PI3K-AKT activation plays a central role in FTC oncogenesis. Multiple lines of evidence corroborate this notion: 1) AKT activation and expression is higher in FTC as compared to normal tissues and other thyroid tumors (22), 2) Cowden syndrome patients, with germline mutations in PTEN, have an increased incidence of FTC (23), 3) transgenic mice engineered to hyperactivate PI3K/AKT form FTCs (24, 25), and 4) in a mouse model of FTC, metastatic potential is Akt-dependent (26). This evidence underscores the importance of AKT hyperactivation in the initiation and progression of FTC, and also suggests that the pathogenesis of FTC is distinct from other forms of well-differentiated thyroid carcinoma, which are driven primarily via activation of the MAPK signaling pathway. Nevertheless, mutations in the RAS pathway and PAX8/PPAR $\gamma$  rearrangements are also found in FTC (27). While the specific pathogenic mechanisms contributed by these alterations remain unclear, there are indications that they too converge on the PI3K-AKT pathway (28). Therefore, it will be therefore interesting to understand in future studies whether these represent cooperative or mutually exclusive events.

Second, we observed that INPP4B is not solely epistatic to PTEN. PTEN and INPP4B are generally thought to be cooperative phosphatases that proximally regulate PI3K at the lipid level. On this basis, we anticipated that *Inpp4b*<sup>-/-</sup> mice would have a phenotype reminiscent of *Pten*<sup>+/-</sup> mice with increased susceptibility to epithelial tumors. Surprisingly, *Inpp4b*<sup>-/-</sup> mice were tumor free and had a tumor free survival of 16-24 months. In addition, crossing *Inpp4b*<sup>-/-</sup> mice with *Pten*<sup>+/-</sup> mice did not accelerate the entire tumor spectrum of *Pten*<sup>+/-</sup> mice by 5-8 months follow-up. Rather, we only observed a significant acceleration of thyroid tumorigenesis. Due to the early mortality that occurred in the *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup>, further studies in conditional *Pten* and *Inpp4b* knockout mice will be needed in order to determine the potential cooperative effect between *Pten* and *Inpp4b* on tumor suppression in other tissues.

Despite the importance of PI3K-AKT signaling in the pathogenesis of FTCs, *Pten*<sup>+/-</sup> mice do not develop FTC. By 10 months of age, they instead develop benign adenomas that do not invade or metastasize. One might speculate that the extent of AKT activation accounts for the difference in thyroid carcinoma aggressiveness. Indeed, we observed increased Akt activation in *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> thyroids when compared to *Pten*<sup>+/-</sup> or *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> thyroids. However, in a previous study, we found that thyroid lesions in *Pten* knock-in mutant mice harboring specific lipid and phosphatase dead *Pten* mutations also demonstrated higher levels of Akt activation than *Pten*<sup>+/-</sup> thyroids similar to *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> thyroids (29). Nevertheless, only 7 – 8 % of these mice developed aggressive thyroid adenocarcinoma, and importantly, there was no occurrence of lung metastasis (29). Furthermore, conditional loss of function of both copies of *Pten* in the thyroid results mainly in follicular adenoma within 12 months of age, which only progresses to invasive FTC at advanced ages, suggesting that even in a setting of maximal activation of PI3K-AKT signaling, other events are needed to trigger FTC (17). In contrast, the *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup>

mice developed aggressive, often metastatic, and always lethal follicular-like carcinoma by 5-6 months of age. The shorter latency to a more aggressive follicular-like carcinoma in *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice further support the notion that while increased Akt activation does play a role in follicular-like thyroid tumorigenesis, it is insufficient in mediating progression and metastases, and that the tumor suppressive function of INPP4B therefore extends beyond its role in suppressing the overall level of PI3K-AKT pathway activation. In this respect, the striking difference between PTEN and INPP4B that emerges from our study is their differential localization at the early endosome where INPP4B but not PTEN could regulate signaling in a localized and specialized fashion.

Beyond the level of AKT activation, isoform-specific AKT signaling plays an important role in mediating cancer progression. In the context of breast cancer, AKT2 has been implicated in metastasis, whereas AKT1 suppresses metastatic dissemination (30). Interestingly, signaling through AKT2 is critical for the development of thyroid neoplasms in *Pten*<sup>+/-</sup> mice (18). Specifically, loss of Akt2 in *Pten*<sup>+/-</sup> mice rescues the development of thyroid adenomas in this model (18). Furthermore, genomic amplification of AKT2 is frequently observed in FTC, but not in anaplastic thyroid carcinoma (31). These findings indicate that AKT2 activation is particularly important in follicular thyroid carcinoma progression and metastasis. Our finding that INPP4B, but not PTEN, localizes to the early endosomes to selectively regulate AKT2 identifies a novel and specific role for INPP4B in the regulation of PI3K-AKT signaling. INPP4B loss could therefore increase the PI(3,4)P<sub>2</sub> pool in the early endosomes, regulate endocytic trafficking and contribute to prolonged AKT2 signaling from the endocytic membranes, through which it mediates its effects on thyroid carcinoma initiation, migration and invasion. Our findings are also in line with recent observation that activation of the endocytic trafficking pathways is critical for

tumor cell migration (32). Therefore, it is possible that the aberrant activation of AKT2 at endosomes might represent the molecular mechanism underlying the characteristic metastatic propensity of FTCs. Intriguingly, although AKT1 is also localized at the early endosomes, INPP4B does not appear to regulate its activation. The exact mechanism underlying the selective regulation of AKT2 by INPP4B remains to be elucidated. Our study nevertheless represents an important first step in the understanding of the mechanism underlying isoform specific and localized AKT regulation.

In conclusion, our study provides strong evidence that INPP4B is not epistatic to PTEN and that INPP4B loss, although insufficient to initiate cancer in the thyroid, can promote FTC progression and metastasis in the context of PTEN haploinsufficiency through the isoform-specific regulation of AKT signaling at the endosomes (Fig. 6). More generally, our findings provide compelling evidence for the critical role of a qualitative regulation of signal transduction in tumorigenesis.



## **METHODS**

### **Mice and histopathological analyses**

Inpp4b knockout mice were generated by Sasaki and colleagues. Total body necropsy and histopathological analyses were performed on cohorts of male and female mice from 4-15 months of age. Mouse tissues were fixed in 4% paraformaldehyde and embedded in paraffin. They were then sectioned and stained with hematoxylin and eosin (H&E) for pathological analyses. The use of these mice and procedures performed were in accordance to NIH-approved guideline, and the Institutional Animal Care and Use Committee (IACUC) at Beth Israel Deaconess Medical Center approved the studies.

### **Studies with Primary cells**

Mouse embryonic fibroblasts (MEFs) were isolated at day E13.5, immortalized with SV40 large T antigen, and maintained in DMEM supplemented with 10% fetal bovine serum, 2mM glutamine, 100 U/ml penicillin and streptomycin (Invitrogen).

### **Cell lines**

All cells were maintained in DMEM or RPMI supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and streptomycin (Invitrogen). N-Thy-Ori-3 cells were purchased from Sigma. Htori and 8505C cells were kindly provided by Dr. Sareh Parangi (MGH); FTC and TPC1 cells were kindly provided by Dr. Orlo H. Clark (UCSF). Cell lines were tested for specific markers by Western blot and qRT-PCR in our laboratory, routinely tested for *Mycoplasma* (MycoAlert; Lonza), but not further authenticated.

### **Human tissue collection**

The Committee for Human Research at Brigham and Women's Hospital approved this study. Thyroid tumors and normal tissue were discarded specimens obtained from patients undergoing

thyroidectomy. The specimens were snap-frozen in the operating room suite with liquid nitrogen and were maintained at -80C until analysis. An endocrine pathologist, who confirmed the histologic diagnosis, evaluated the specimens.

### **Western blotting and immunohistochemistry**

Cells and tissues were lysed with RIPA buffer (50mM Tris [pH8], 150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 1mM EDTA and protease and phosphatase inhibitor cocktail [Roche]). For western blotting, the following antibodies were used: anti-AKT (9272, 1:1000), anti-p-AKT (pSer473, 9271, 1:1000; pThr308, 9275, 1:1000), anti-AKT1(2938, 1:1000), anti-AKT2(3063, 1:1000 and 5239, 1:1000), anti-p-AKT1 (pSer473)(9018, 1:1000), anti-p-AKT2 (pSer474)(8599, 1:1000), anti-PTEN (9559, 1:1000), anti-INPP4B(8450, 1:1000) were from Cell Signaling Technology. Please note that anti-AKT2 (3063) and (5239) cross-reacted with different unspecific bands, with a lower AKT2 specific band for (3063) and an upper specific band for (5239) as indicated. The specific bands are those that identified a protein of the expected molecular weight, while unspecific bands were migrating at very different molecular weights. Different and well-established antibodies against AKT2 (33, 34) were used in two independent laboratories in order to corroborate the reported findings. Anti-INPP4B (81269, 1:1000) was from Epitomics. Anti-HSP90 (610419, 1:3000) was from BD Biosciences anti- $\beta$ -actin (A3853, 1:5000) was from Sigma. The characterization of anti-INPP4B (81269) has been shown in the Suppl Fig. 2. p-AKT1 and p-AKT2 band intensities were normalized to the corresponding AKT1 and AKT2 expression levels, except in Figure 4G where they were normalized to RAB5. Band intensities were quantified with ImageJ software. For immunohistochemistry, anti-thyroglobulin antibody (80783, 1:2000) was from Abcam and anti-p-Akt (pSer473, 4060, 1:100) was from Cell Signaling Technology.

## **Immunofluorescence**

Cells were grown on coverslips, fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton or pre-chilled methanol. Cells were rinsed with PBS, blocked and then incubated with primary antibody, followed by incubation with Alexa Fluor conjugated secondary antibodies (Life Technologies). Coverslips were mounted with ProLong Gold Antifade reagent with DAPI (Life Technologies). Confocal images of cells were acquired with LSM510META Confocal Laser System (BIDMC) and Zeiss Observer-Z1 microscope equipped with Apotome (University of Torino). Primary antibodies used: anti-INPP4B (Atlas, 37682, 1:50), anti-PI3K-C2 $\alpha$  (anti-p170) (BD, 611046, 1:25) anti- $\gamma$ -tubulin (Sigma, GTU-88, 1:100), anti-Rab5 (BD, 610261, 1:25 and Cell Signaling Technology, 3547, 1:50) anti- $\alpha$ -tubulin (Sigma, T6074, 1:100), anti-PtdIns(3,4P)<sub>2</sub> and anti-PtdIns(3,4,5)P<sub>3</sub> (Echelon, Z-P034b, 1:50 and Z-P345, 1:50), anti-SNX9 (Proteintech, 15721-1-AP, 1:400), and anti-AKT2 (Cell Signaling Technology, 3063, 1:100).

## **Early endosome purification**

Cells were gently homogenized in the homogenization buffer (250mM sucrose, 3mM imidazole, pH 7.4 with protease inhibitor cocktail). The samples were centrifuged at 3000 rpm to remove nuclei and cell debris. Postnuclear supernatant (PNS) was subsequently separated by sucrose gradient centrifugation into different cellular fractions. In detail, the PNSs were adjusted to 40.6% sucrose using a stock solution (62% sucrose, 3mM imidazole pH 7.4), loaded at the bottom of centrifugation tubes (SW55), then sequentially overlaid with 1.5 ml 35% sucrose solution (35% sucrose, 3mM imidazole pH 7.4) followed by 1ml 25% solution (25% sucrose, 3mM imidazole pH 7.4) and 1ml of homogenization buffer on top of the load. After 1 hour centrifugation, at 35000 rpm 4°C, early endosomes (EE) were recovered from interphase between 35% and 25% layers, late endosomes (LE) were recovered from uppermost portion of

25% phase, and heavy membranes (HM) including ER, Golgi and plasma membranes were recovered from lowest interphase. EE, LE and HM were then precipitated with methanol/chloroform loaded in SDS-PAGE for western blot analyses.

### **RNA isolation and RT-qPCR**

Total RNA was purified from cell lines and tissues using the PureLink RNA Mini Kit (Invitrogen). For qPCR analysis, 2ug of total RNA was reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR-Green qPCR analysis was then performed using Applied Biosystems StepOnePlus in accordance to the manufacturer's protocol. Each target was run in triplicate, and expression levels were normalized to mouse hypoxanthine-guanine phosphoribosyltransferase (*HPRT*) or human porphobilinogen (PBGD).

### **Genotyping**

The following genotyping primers were used:

Inpp4b del1: GTTTACATTTGACAGGGTGGTTGG

Inpp4b del2: TGCTGTCGCCGAAGAAGTTA

Inpp4b del3: CCTGCCATGGGTAGATTTCT

Pgen-1: TGGGAAGAACCTAGCTTGGAGG

Pgen-3: ACTCTACCAGCCCAAGGCCCGG

3193: CGAGACTAGTGAGACGTGCTACTTCC

### **5-Aza-2'-deoxycytidine treatment**

Cells were briefly treated with 3uM of 5-Aza-2'-deoxycytidine for 5 days. After that, the cells were harvested for RNA and protein analysis.

### **Growth proliferation assay**

Cells were plated at a density of  $2.5 \times 10^4$  cells/well in 12-well plates and each sample was plated in triplicate. Plates were collected on day 0, day 2, day 4 and day 6. The wells were washed with PBS and cells were fixed with 4% paraformaldehyde (Santa Cruz Biotechnology). Wells were stained with 0.1% Crystal Violet solution, washed and dried. The absorbed stained was then solubilized with 10% acetic acid, and the absorbance was measured at 595nm.

### **Soft-agar colony formation assay**

Soft-agar colony formation assay was performed by first plating 6-well tissue culture plates with 0.6% Noble agar/growth media and allowed to solidify at room temperature.  $1 \times 10^5$  thyroid cancer cell lines in 0.3% Noble agar/growth media were then seeded as the top layer. Each cell line was seeded in triplicate. The soft agar was allowed to solidify at room temperature, then placed in the incubator at 37°C. Fresh growth media was added every week, and colonies were counted and photographed after 2 weeks.

### **Measurement of TSH levels**

Serum was collected from, *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice. The mice were between 3-5 months of age, and at least 4 mice in each genotype were tested. Briefly, blood was allowed to clot at 4°C for at least 2 hours. It was then centrifuged at 1000xg for 15 minutes. The serum was carefully removed and frozen at -20°C. For testing, we used the ultrasensitive thyroid-stimulating hormone (U-TSH) ELISA kit from MyBioSource (MBS042764).

### **Bisulfite sequencing**

Genomic DNA samples were collected and treated with bisulfite using the EpiTect Bisulfite kit (Qiagen) according to the manufacturer's recommendations. PCR amplification was performed

with primers specific for the methylated and unmethylated alleles, as described in Yuen et al. (12).

### **Statistical analysis**

For quantitative data, data sets were generally analyzed using the unpaired, two-tailed Student's *t* tests (GraphPad Prism, GraphPad Software).  $p < 0.05$  was considered significant.

## **Authors' Contributions**

**Conception and design:** C.L. Chew, D.T. Ruan, A. Lunardi, L. Salmena, P.P. Pandolfi

**Development of methodology:** C.L. Chew, F. Gulluni, D.T. Ruan, A. Lunardi, M. Chen, L. Salmena, A. Papa

**Acquisition of data:** C.L. Chew, F. Gulluni, D.T. Ruan, M. Chen, C. Ng, J. Fung

**Analysis and interpretation of data (e.g. statistical analysis, H&E and IHC interpretation):**  
C.L. Chew, D.T. Ruan, A. Lunardi, M. Chen, M. Nishino, R.T. Bronson, E. Hirsch, P.P. Pandolfi

**Writing, review, and/or revision of the manuscript:** C.L. Chew, D.T. Ruan, A. Lunardi, M. Chen, P.P. Pandolfi

**Administrative, technical, or material support:** C.L. Chew, D.T. Ruan, A. Lunardi, A. Papa, J.G. Clohessy, J. Sasaki, T. Sasaki, L. Longo

**Study supervision:** C.L. Chew, A. Lunardi, D.T. Ruan, A. Papa, P.P. Pandolfi

**Carried out experiments:** C.L. Chew, F. Gulluni, M. Chen, A. Lunardi

**Provided histology and immunohistochemistry:** C. Ng, J. Fung

## **Acknowledgements**

The authors thank all members of the Pandolfi laboratory for critical discussion, Lauren Fawls for editing the manuscript, Kelsey Berry for technical assistance and Justine Barletta for help with histopathological interpretation. The authors are grateful to Min Sup Song and Su Jung Song for insightful discussion.

## **Grant Support**

This work has been supported by NIH grant U01 CA141496 to P.P.P. C.L.C. was supported by the A\*STAR National Science Scholarship (Singapore).



## Reference

1. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nature reviews Drug discovery*. 2014;13:140-56.
2. Toker A, Marmiroli S. Signaling specificity in the Akt pathway in biology and disease. *Advances in biological regulation*. 2014;55:28-38.
3. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. *Cancer research*. 2003;63:196-206.
4. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. *Cancer research*. 2004;64:3171-8.
5. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. *The Journal of cell biology*. 2005;171:1023-34.
6. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. *Nature genetics*. 1998;19:348-55.
7. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. *Nature reviews Cancer*. 2011;11:289-301.

8. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al. A genetic screen for candidate tumor suppressors identifies REST. *Cell*. 2005;121:837-48.
9. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. *Cancer cell*. 2009;16:115-25
10. Fedele CG, Ooms LM, Ho M, Vieuxseux J, O'Toole SA, Millar EK, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107:22231-6.
11. Perez-Lorenzo R, Gill KZ, Shen CH, Zhao FX, Zheng B, Schulze HJ, et al. A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. *The Journal of investigative dermatology*. 2014;134:1359-68.
12. Yuen JW, Chung GT, Lun SW, Cheung CC, To KF, Lo KW. Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma. *PloS one*. 2014;9:e105163.
13. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. *Cancer research*. 2011;71:572-82.
14. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. *Cancer cell*. 2010;18:11-22.
15. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science (New York, NY)*. 1997;275:665-8.

16. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten<sup>+/-</sup> mice. *Science (New York, NY)*. 1999;285:2122-5.
17. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. *Oncogene*. 2010;29:5678-86.
18. Xu PZ, Chen ML, Jeon SM, Peng XD, Hay N. The effect Akt2 deletion on tumor development in Pten<sup>(+/-)</sup> mice. *Oncogene*. 2012;31:518-26.
19. Walz HA, Shi X, Chouinard M, Bue CA, Navaroli DM, Hayakawa A, et al. Isoform-specific regulation of Akt signaling by the endosomal protein WDFY2. *The Journal of biological chemistry*. 2010;285:14101-8.
20. Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciruolo E, et al. PI3K class II alpha controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. *Developmental cell*. 2014;28:647-58.
21. Posor Y, Eichhorn-Gruenig M, Puchkov D, Schoneberg J, Ullrich A, Lampe A, et al. Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. *Nature*. 2013;499:233-7.
22. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. *Cancer research*. 2001;61:6105-11.
23. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. *The Journal of clinical endocrinology and metabolism*. 2011;96:E2063-71.

24. Furuya F, Hanover JA, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103:1780-5.
25. Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, et al. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. *The Journal of clinical endocrinology and metabolism*. 2014;99:E804-12.
26. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. *Endocrinology*. 2005;146:4456-63.
27. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *The Journal of clinical endocrinology and metabolism*. 2003;88:2318-26.
28. Diallo-Krou E, Yu J, Colby LA, Inoki K, Wilkinson JE, Thomas DG, et al. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. *Endocrinology*. 2009;150:5181-90.
29. Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, et al. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. *Cell*. 2014;157:595-610.

30. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer research*. 2009;69:5057-64.
31. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. *The Journal of clinical endocrinology and metabolism*. 2008;93:3106-16.
32. Palamidessi A, Frittoli E, Garre M, Faretta M, Mione M, Testa I, et al. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. *Cell*. 2008;134:135-47.
33. Chin RY, Yuan X, Balk SP, Toker, A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. *Cancer discovery*. 2014;4:942:55.
34. Ullal AV, Peterson V, Agasti SS, Tuang S, Juric D, Castro CM et al. Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. *Sci Transl Med*. 2014;6:219ra9.

## FIGURE LEGENDS

**Figure 1. Generation and Characterization of *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice. A.** Diagram representing the structure of INPP4B, which contains an N-terminus C2 domain and a C-terminus phosphatase domain harboring the phosphatase catalytic motif CX5R. **B.** Schematic map of the WT *Inpp4b* locus (top), targeting vector (upper middle) and predicted targeted allele (lower middle) and knockout allele (bottom). **C.** Table depicting the observed versus the expected numbers of mice of the respective genotypes from a *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Inpp4b*<sup>+/-</sup> cross. These values gave a  $\chi^2$  of 3.26, which is lower than the critical value of 11.070 which would yield an  $\alpha=0.05$ . Thus, we conclude that the mutants were born following Mendelian frequencies.

**Figure 2. Loss of *Inpp4b* in *Pten*<sup>+/-</sup> mice leads to follicular thyroid carcinoma. A.** Kaplan-Meier survival curve of *Pten*<sup>+/-</sup>, *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice. **B. Top panel:** gross anatomy of representative thyroids from mice of the indicated genotypes. White arrows point to

the location of the thyroid. *Bottom panel*: dissected thyroids from mice of the indicated genotypes; Scale bar, 2mm. *C. Left panel*: H&E staining of a follicular thyroid carcinoma (FTC)-like thyroid tumor which is thinly encapsulated with microfollicular architecture. *Right panel*: H&E staining of a follicular variant of papillary thyroid carcinoma (FV-PTC)-like thyroid tumor. Middle and bottom panels highlight nuclear atypia characteristic of FV-PTC, including intranuclear pseudoinclusions (arrow). Scale bars, top and middle panels:100 $\mu$ m, bottom panel: 20  $\mu$ m, **D. Top panel**: H&E staining of thyroid tumor and lung metastases from *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> mice; *middle & bottom panel*: thyroglobulin and p-Akt (Ser473) staining. Scale bar, 100 $\mu$ m. Insets show thyroid cancer cells. Blue arrows point to the location of the metastases in the lungs.

**Figure 3. INPP4B expression is reduced in human follicular thyroid cell lines and human surgical specimens.** **A.** Western blot analysis of thyroid cancer cell lines for INPP4B and PTEN expression. Arrow indicates specific band. The arrowhead indicates the specific band of INPP4B protein. **B.** RT-qPCR analysis of thyroid cancer cell lines for INPP4B transcript levels. **C.** Western blot analysis of thyroid cancer lines for AKT activation on both Serine 473 and Threonine 308 residues. **D.** RT-qPCR analysis of *INPP4B* in unmatched normal versus FTC patient tumor samples. **E-F.** Thyroid cancer cell lines were treated with 3 $\mu$ M 5-Aza-2'-deoxycytidine for 5 days. Panel shows transcript (**E**) and protein analysis of INPP4B expression and AKT activation levels in DMSO versus 5-Aza treated FTC cells. (**F**). Arrows indicate specific band (see also Methods). AKT2 antibody used is (5239).

**Figure 4. Loss of *Inpp4b* in *Pten*<sup>+/-</sup> cells leads to increased Akt activation.** **A-B.** Western blot analysis of lysates from *Pten*<sup>+/-</sup> (n=3; ~10-11months), *Pten*<sup>+/-</sup>*Inpp4b*<sup>+/-</sup> (n=2; ~6-8months) and *Pten*<sup>+/-</sup>*Inpp4b*<sup>-/-</sup> (n=3; ~6 months) thyroid tissues (**A**), lysates from immortalized MEFs after

serum starvation-restimulation. The MEFs were stimulated with serum for the indicated amount of time. **(B).** **C.** Western blot analysis of total lysate from different thyroid cancer cells. Please note that the AKT2 antibody used in **A-B** (5239) is different from **C** (3063), resulting in the appearance of different unspecific bands. Arrows indicate specific band (see also Methods). **D-E.** Western blot analysis of cell fractions from TPC1 cells. HM: cytosolic/heavy membranes; EE: early endosome; LE: late endosome; PNS: postnuclear supernatant. Arrow indicates specific band. AKT2 antibody used is (3063). **F.** Western blot analysis of phosphorylated Akt1 and phosphorylated Akt2 in different cell fractions derived from TPC1 cells infected with either a non-targeting shRNA or an shRNA that targets INPP4B. **G.** Western blot analysis of phosphorylated Akt1 and phosphorylated Akt2 in different cell fractions derived from FTC236 cells treated with either DMSO or 3uM 5-Aza for 5days.

**H.** Immunofluorescence of PI(3,4)P<sub>2</sub> and tubulin in TPC1 cells infected with either a non-targeting shRNA or an shRNA that targets INPP4B. Scale bars, 20 μm. **I.** Immunofluorescence of INPP4B, AKT2, PI3K-C2α and RAB5 in TPC1 cells. Scale bars, 5μm. **J.** Immunofluorescence of PI(3,4)P<sub>2</sub> and SNX9 in TPC1 and FTC236 cells. Scale bars, 20 μm.

**Figure 5. Knockdown of INPP4B in thyroid cancer cells provides an advantage for anchorage independent growth.** **A.** RT-qPCR analysis of *INPP4B* upon shRNA-mediated knockdown. **B.** Western blot analysis of INPP4B levels in TPC1 and 8505C cell lines after shRNA-mediated knockdown. **C.** Proliferation of TPC1 and 8505C cell lines infected with either a non-targeting shRNA or a shRNA that targets INPP4B. Cells were cultured in complete media (10% serum), stained with crystal violet, and lysed. Absorbance was measured at OD595nm. **D-E.** Soft agar colony formation assay of cells infected with either a non-targeting shRNA or an




shRNA which targets INPP4B. Cells were grown in soft agar for 2 weeks before being photographed (**D**) and the number of colonies was then counted (**E**).

**Figure 6. Model for the role of INPP4B and PTEN loss in FTC progression and metastasis.**


INPP4B and PTEN control both activation level and subcellular localization of PI3K/AKT signalling to oppose thyroid tumorigenesis.

Fig. 1 Chew et al

A




B




C

	Observed	Expected	(O-E) <sup>2</sup>	$\chi^2$
WT	20	17	9	0.52941
Inpp4b <sup>+/-</sup>	33	34	1	0.02941
Inpp4b <sup>-/-</sup>	18	17	1	0.05882
Pten <sup>+/-</sup>	20	17	9	0.52941
Pten <sup>+/-</sup> Inpp4b <sup>+/-</sup>	26	34	64	1.88235
Pten <sup>+/-</sup> Inpp4b <sup>-/-</sup>	19	17	4	0.23529
TOTAL	136	136		3.26471


**Fig. 2 Chew et al**



**Fig. 3** Chew et al



**Fig. 4** Chew et al



**Fig. 5** Chew et al





Fig. 6 Chew et al



# CANCER DISCOVERY

## In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K/AKT signaling at endosomes

Chen Li Chew, Andrea Lunardi, Federico Gulluni, et al.

*Cancer Discovery* Published OnlineFirst April 16, 2015.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/2159-8290.CD-14-1347">10.1158/2159-8290.CD-14-1347</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerdiscovery.aacrjournals.org/content/suppl/2015/04/15/2159-8290.CD-14-1347.DC1">http://cancerdiscovery.aacrjournals.org/content/suppl/2015/04/15/2159-8290.CD-14-1347.DC1</a>
<b>Author Manuscript</b>	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cancerdiscovery.aacrjournals.org/content/early/2015/04/15/2159-8290.CD-14-1347">http://cancerdiscovery.aacrjournals.org/content/early/2015/04/15/2159-8290.CD-14-1347</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.